Envista (NYSE:NVST) Stock Gets Price Target Trim from Piper Sandler

Envista (NYSE:NVST) had its price target trimmed by Piper Sandler from $28.00 to $26.00 in a report issued on Friday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft set a $32.00 price target on shares of Envista in a report on Thursday, September 3rd. Barclays lowered their price objective on shares of Envista from $34.00 to $32.00 and set an “overweight” rating on the stock in a research note on Thursday, June 11th. Wall Street Zen cut Envista from a “strong-buy” rating to a “buy” rating in a report on Saturday, September 5th. Needham & Company LLC reiterated a “hold” rating on shares of Envista in a research report on Friday, September 18th. Finally, Robert W. Baird set a $34.00 price objective on Envista in a research note on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $29.64.

Envista Trading Down 0.2%

Envista stock opened at $22.95 on Friday. Envista has a 12-month low of $18.77 and a 12-month high of $30.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.43 and a quick ratio of 2.07. The stock has a market capitalization of $3.69 billion, a PE ratio of 39.58, a price-to-earnings-growth ratio of 1.17 and a beta of 0.89. The firm has a 50 day simple moving average of $25.95 and a 200-day simple moving average of $25.73.

Envista (NYSE:NVST) last announced its earnings results on Wednesday, August 5th. The company reported $0.41 EPS for the quarter, topping the consensus estimate of $0.34 by $0.07. The firm had revenue of $730.50 million for the quarter, compared to analysts’ expectations of $716.11 million. Envista had a return on equity of 7.88% and a net margin of 3.33%. The firm’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.26 earnings per share. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. As a group, equities research analysts expect that Envista will post 1.53 EPS for the current fiscal year.

Insider Buying and Selling at Envista

In other news, SVP Mischa Reis sold 8,000 shares of Envista stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $27.50, for a total transaction of $220,000.00. Following the transaction, the senior vice president owned 27,321 shares in the company, valued at approximately $751,327.50. The trade was a 22.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.99% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new position in shares of Envista in the second quarter worth $25,000. Nykredit A S acquired a new stake in Envista during the second quarter valued at $52,000. Elevation Wealth Partners LLC boosted its position in Envista by 262.9% during the third quarter. Elevation Wealth Partners LLC now owns 2,406 shares of the company’s stock valued at $56,000 after purchasing an additional 1,743 shares during the last quarter. C M Bidwell & Associates Ltd. purchased a new position in Envista in the second quarter valued at about $63,000. Finally, Parkside Financial Bank & Trust grew its stake in Envista by 246.2% in the second quarter. Parkside Financial Bank & Trust now owns 3,071 shares of the company’s stock valued at $81,000 after purchasing an additional 2,184 shares in the last quarter.

Envista Company Profile

Envista Holdings Corporation (NYSE: NVST) is a global dental-products and technologies company that develops, manufactures and markets equipment, consumables and digital solutions for dental professionals, laboratories and specialists. Its offerings support diagnosis, treatment planning, restorative dentistry, orthodontics, implant dentistry and related clinical procedures.

The company’s portfolio includes dental imaging systems and software, treatment units, handpieces, infection-control products, restorative materials, endodontic products, orthodontic brackets and aligners, dental implants, prosthetic components and laboratory solutions.